Graf Susan E
VP, Corp Development & Strateg at NPS PHARMACEUTICALS INC
- Sold, on record
- $308k
- Dollars the filings state
- Form 4 sales
- 1
- Latest Feb 10, 2015
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- NPS PHARMACEUTICALS INCVP, Corp Development & Strateg
Sales by reason
0
Routine
0
Plan not stated
0
No plan
1
Unusual
Form 4 sales per year, every sale on record.
Timeline
- Feb 10, 2015Unusual
Sold 63.8% of their holdings
$308k6,711 shares at $45.87
1 of 1
Every transaction
| Traded | Filed | Stock | Role | What | Amount | Price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Aug 21, 2026 | AARD | Director | AwardedStock Option (right to buy) | 44,964 | 44,964 | SEC | ||
| Jun 4, 2026 | Jun 5, 2026 | CGON | Director | AwardedDirector Stock Option (right to buy) | 9,354 | 9,354 | SEC | ||
| Jun 11, 2025 | Jun 13, 2025 | AARD | Director | AwardedStock Option (right to buy) | 30,508 | 30,508 | SEC | ||
| Jun 5, 2025 | Jun 6, 2025 | CGON | Director | AwardedDirector Stock Option (right to buy) | 24,165 | 24,165 | SEC | ||
| Oct 4, 2024 | Oct 7, 2024 | CGON | Director | AwardedStock Option (Right to Buy) | 15,600 | 15,600 | SEC | ||
| Jun 9, 2023 | Jun 9, 2023 | Finch Therapeutics Group, Inc. | Director | Bought | 5,010 | $0.27 | $1k | 5,010 | SEC |
| Jun 8, 2023 | Jun 9, 2023 | Finch Therapeutics Group, Inc. | Director | AwardedStock Option (right to buy) | 10,000 | 10,000 | SEC | ||
| Jun 13, 2022 | Jun 15, 2022 | Finch Therapeutics Group, Inc. | Director | AwardedStock Option (right to buy) | 44,843 | 44,843 | SEC | ||
| Apr 23, 2021 | Apr 27, 2021 | Finch Therapeutics Group, Inc. | Director | AwardedStock Option (right to buy) | 23,419 | 23,419 | SEC | ||
| Feb 9, 2018 | Feb 13, 2018 | Epizyme, Inc. | Chief Business Officer | AwardedStock Option (Right to Buy) | 106,344 | 106,344 | SEC | ||
| Feb 8, 2017 | Feb 9, 2017 | Epizyme, Inc. | Chief Business Officer | AwardedStock Option (Right to Buy) | 109,866 | 109,866 | SEC | ||
| Apr 25, 2016 | Apr 26, 2016 | Epizyme, Inc. | Chief Business Officer | AwardedStock Option (Right to Buy) | 178,642 | 178,642 | SEC | ||
| Feb 21, 2015 | Feb 24, 2015 | NPS PHARMACEUTICALS INC | VP,Corp Development & Strategy | Tendered | 4,761 | $46.00 | $219k | 0 | SEC |
| Feb 21, 2015 | Feb 24, 2015 | NPS PHARMACEUTICALS INC | VP,Corp Development & Strategy | Returned to the companyStock Options (right to buy) | 78,538 | 0 | SEC | ||
| Feb 12, 2015 | Feb 20, 2015 | NPS PHARMACEUTICALS INC | VP,Corp Development & Strategy | Exercised or settledRestricted Stock Units | 1,445 | 2,893 | SEC | ||
| Feb 12, 2015 | Feb 20, 2015 | NPS PHARMACEUTICALS INC | VP,Corp Development & Strategy | Exercised options | 1,445 | 5,245 | SEC | ||
| Feb 12, 2015 | Feb 20, 2015 | NPS PHARMACEUTICALS INC | VP,Corp Development & Strategy | Withheld for tax | 484 | $45.85 | $22k | 4,761 | SEC |
| Feb 12, 2015 | Feb 20, 2015 | NPS PHARMACEUTICALS INC | VP,Corp Development & Strategy | AwardedRestricted Stock Units | 10,905 | 10,905 | SEC | ||
| Feb 10, 2015 | Feb 11, 2015 | NPS PHARMACEUTICALS INC | VP, Corp Development & Strateg | Sold | 6,711 | $45.87 | $308k | 3,800 | SEC |
| Feb 10, 2015 | Feb 11, 2015 | NPS PHARMACEUTICALS INC | VP, Corp Development & Strateg | Exercised or settledEmployee Stock Options (right to buy) | 6,711 | 41,289 | SEC | ||
| Feb 10, 2015 | Feb 11, 2015 | NPS PHARMACEUTICALS INC | VP, Corp Development & Strateg | Exercised options | 6,711 | $14.90 | $100k | 10,511 | SEC |
| Jun 17, 2014 | Jun 19, 2014 | NPS PHARMACEUTICALS INC | VP,Corp Development & Strategy | Exercised or settledRestricted Stock Units | 5,788 | 11,577 | SEC | ||
| Jun 17, 2014 | Jun 19, 2014 | NPS PHARMACEUTICALS INC | VP,Corp Development & Strategy | Exercised options | 5,788 | 5,788 | SEC | ||
| Jun 17, 2014 | Jun 19, 2014 | NPS PHARMACEUTICALS INC | VP,Corp Development & Strategy | Withheld for tax | 1,988 | $33.10 | $66k | 3,800 | SEC |
| Feb 12, 2014 | Feb 14, 2014 | NPS PHARMACEUTICALS INC | VP Corp Development & Strategy | AwardedEmployee Stock Options (right to buy) | 16,212 | 4,338 | SEC | ||
| Jun 17, 2013 | Jun 18, 2013 | NPS PHARMACEUTICALS INC | VP Corp Development & Strategy | AwardedEmployee Stock Options (right to buy) | 65,365 | 17,365 | SEC |
Sales and notices (1)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Feb 10, 2015 | Feb 11, 2015 | NPS PHARMACEUTICALS INC | VP, Corp Development & Strateg | Form 4 sale | 6,711 | $308k | 63.8% | Unusual | SEC |